BEBT 808
Alternative Names: BEBT-808Latest Information Update: 03 Apr 2023
At a glance
- Originator BeBetter Med
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity; Type 2 diabetes mellitus
Most Recent Events
- 03 Apr 2023 Preclinical trials in Obesity in China (PO) before April 2023 (BeBetter Med pipeline, April 2023)
- 03 Apr 2023 Preclinical trials in Type 2 diabetes mellitus in China (PO) before April 2023 (BeBetter Med pipeline, April 2023)
- 03 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical study in Type 2 diabetes mellitus were released by BeBetter Med (BeBetter Med website, April 2023)